Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Southfield, MI
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Southfield, MI
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Kalispell, MT
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Kalispell, MT
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Reno, NV
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Edison, NJ
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Edison, NJ
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Summit, NJ
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Summit, NJ
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Brooklyn, NY
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Columbus, OH
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Portland, OR
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Portland, OR
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Bryn Mawr, PA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Hershey, PA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Paoli, PA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Paoli, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Columbia, SC
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Houston, TX
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Mechanicsville, VA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Midlothian, VA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Midlothian, VA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Richmond, VA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Richmond, VA
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
Clinical Research Facility
mi
from
Mobile, AL
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated:  10/19/2015
mi
from
Edmonton,
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
Status: Enrolling
Updated: 10/19/2015
mi
from
Edmonton,
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
University of Alabama
mi
from
Birmingham, AL
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, University of Miami
mi
from
Miami, FL
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Northwestern University
mi
from
Chicago, IL
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, Hutzel Hospital
mi
from
Detroit, MI
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, Hutzel Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
St. Luke's Roosevelt Hospital
mi
from
New York, NY
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
St. Luke's Roosevelt Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Forsyth Memorial Hospital, Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Forsyth Memorial Hospital, Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
The University Hospital, University of Cincinnati
mi
from
Cincinnati, OH
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
The University Hospital, University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Case Western University
mi
from
Cleveland, OH
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, Ohio State University
mi
from
Columbus, OH
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
MCP Hahnemann University
mi
from
Philadelphia, PA
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
MCP Hahnemann University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN Magee Womens Hospital
mi
from
Pittsburgh, PA
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN Magee Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Women and Infants Hospital
mi
from
Providence, RI
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
Dept of OB/GYN, Southwestern Medical Center, University of Texas
mi
from
Dallas, TX
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
Dept of OB/GYN, Southwestern Medical Center, University of Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
The University of Texas, Houston
mi
from
Houston, TX
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated:  10/19/2015
University of Utah Medical Center
mi
from
Salt Lake City, UT
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
Status: Enrolling
Updated: 10/19/2015
University of Utah Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
UCLA Stroke Network
mi
from
Los Angeles, CA
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
UCLA Stroke Network
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
The Stroke Center at Hartford Hospital
mi
from
Hartford, CT
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
The Stroke Center at Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
Lakeland Regional Medical Center
mi
from
Lakeland, FL
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
Lakeland Regional Medical Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
OCALA Neurodiagnostic Center
mi
from
Ocala, FL
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
OCALA Neurodiagnostic Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
Ruan Neurology Clinic and Clinical Research Center
mi
from
Des Moines, IA
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
Ruan Neurology Clinic and Clinical Research Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
Via Christi Regional Medical Center
mi
from
Wichita, KA
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
University of Kentucky, Sanders Brown Center on Aging/Stroke Program
mi
from
Lexington, KY
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
University of Kentucky, Sanders Brown Center on Aging/Stroke Program
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated:  10/19/2015
University of Massachusetts, Memorial Health Center, Department of Neurology
mi
from
Worcester, MA
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Status: Enrolling
Updated: 10/19/2015
University of Massachusetts, Memorial Health Center, Department of Neurology
mi
from
Worcester, MA
Click here to add this to my saved trials